15 results about "Nucleic acid binding protein" patented technology

The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with protease-conditional recombinase (hereinafter “ProRec”) activity. Namely a new cre recombinase pro enzyme, compositions / kit and sensors comprising the cre recombinase pro enzyme of the present disclosure. Namely, a cre recombinase pro-enzyme, for identifying and quantifying proteolytic activity in a disease or an infection, comprising intein mediated circularization, a flip-excision cassette comprising an output reporter and / or effector protein; a linker sequence cleavable by a protease.

The present disclosure relates to lipid nanoparticles for delivery of RNA, the lipid nanoparticle comprising therein a nucleic acid-binding protein or peptide (e.g., a RNA-binding protein or peptide) bound to the RNA, and uses thereof.

The application provides a method for separating nucleic acid binding proteins in solid tissue cells, and the method comprises the following steps: step S1, preparing solid tissue into a cell suspension 1; step S2, cross-linking the cell suspension 1 by using a cross-linking agent to form a cell suspension 2 with nucleic acid-NABPs complexes; step S3, lysing red blood cells in the cell suspension 2 of step S2 to remove high-abundance protein interference; step S4, after the cells treated in step S3 are lysed by using an organic reagent, the nucleic acid-NABPs complexes in the solid tissue cells are selectively enriched by using affinity chromatography; and step S5, after the nucleic acid-NABPs complexes obtained in step S4 are de-cross-linked, nucleic acid binding proteins (NABPs) in the solid tissue cells are obtained.

Methods for preparing a sample containing nucleic acids are provided herein. In some embodiments, the method comprises heating the sample above its boiling point in a closed heating chamber to rapidly extract nucleic acids from biological entities present in the sample; and analyzing the nucleic acids from the heat-treated sample. In some embodiments, the treated sample may contain one or more reagents selected from the group consisting of chelating agents, single-stranded nucleic acid-binding proteins, reducing agents, and stabilizers.

Methods and compositions for purifying a nucleic acid preparation. The methods include contacting a nucleic acid preparation including single-stranded ribonucleic acid (ssRNA) with a double-stranded ribonucleic acid binding protein (dsRBP) that specifically binds to double-stranded ribonucleic acid (dsRNA) and is optionally immobilized on a solid support before or after the dsRBP-dsRNA complex is formed to remove dsRNA from a mixed nucleic acid preparation.

The present invention discloses a method for identifying nucleic acid binding proteins based on protein graphs and protein language models, and belongs to the field of bioinformatics technology. The present invention combines high-dimensional sequence features extracted by the ProtT5 protein language model with three-dimensional structural information predicted by AlphaFold, so that the model can simultaneously capture rich feature information of sequence and structure, significantly improving the accuracy and reliability of NABPs prediction; the representation ability of sequence features is enhanced by both the GAT network and the BiLSTM network, so that the constructed prediction model can more comprehensively understand the important information in the protein sequence, thereby improving the prediction performance of NABPs; the features output by the GAT network and the BiLSTM network are fused, and NABPs are classified by MLP, so that the prediction model can fully utilize feature information from different sources, thereby improving the performance and robustness of NABPs prediction.

The present invention relates to methods for obtaining an enriched population of target polynucleotides using synthetic single guide RNAs (sgRNAs) for sgRNA-guided nucleic acid binding proteins, and to methods for obtaining a pool of personalized target-agnostic synthetic single guide RNAs (sgRNAs) for sgRNA-guided nucleic acid binding proteins. Also provided are kits comprising a pool of sgRNAs obtainable by the methods of the invention, the use of a pool of sgRNAs obtainable by the methods of the invention, and methods of monitoring a disease condition.

Methods for proximity ligation of nucleic acids complexed with nucleic acid binding proteins using transposase to cleave the nucleic acids, and ligating the products are provided. Compositions for said methods are further provided.

The invention discloses a pyrazolone compound, a pharmaceutical composition containing the pyrazolone compound and application of the pyrazolone compound and the pharmaceutical composition. The pyrazolone compound is a compound shown in a general formula I or a tautomer, a raceme, a meso-raceme, an enantiomer, a diastereoisomer and pharmaceutically acceptable salt of the compound. The pyrazolone compound provided by the invention can inhibit a Z-type nucleic acid binding protein 1 (ZBP1) signal channel, and has an application prospect in treatment of diseases related to ZBP1 protein functions.

The invention discloses a nucleic acid binding protein recognition method based on a protein map and a protein language model, and belongs to the technical field of bioinformatics. According to the method, high-dimensional sequence features extracted by a ProtT5 protein language model are combined with three-dimensional structure information predicted by AlphaFold, so that the model can capture rich feature information of the sequence and the structure at the same time, and the accuracy and reliability of NABPs prediction are remarkably improved; the expression capability of sequence features is enhanced through the GAT network and the BiLSTM network, so that the constructed prediction model can more comprehensively understand important information in the protein sequence, and the prediction performance of NABPs is improved; the features output by the GAT network and the BiLSTM network are fused, and NABPs classification is performed through the MLP, so that the prediction model can make full use of feature information from different sources, and the NABPs prediction performance and robustness are improved.

The invention relates to the field of medicine, in particular to application of nucleic acid binding protein ZBP1 in treatment of brachial plexus root avulsion injury. Brachial plexus root avulsion and replantation operations are respectively carried out on a WT mouse and a ZBP1 gene knockout mouse, and it is confirmed that ZBP1 gene knockout can promote motor function recovery, reduce motor neuron death, increase myelin regeneration and relieve muscle atrophy. Meanwhile, the ZBP1 gene knockout can reduce the death of motor neurons and promote the recovery of motor functions. The invention aims to provide a novel treatment strategy and a medicine development and research direction for treating brachial plexus root avulsion injury.

A fusion protein, according to one aspect, enables effective base editing within organelles, and provides an effect of enabling genetic base editing of both cell nucleus and organelles by using a single fusion protein.

The present disclosure provides a single-chain binding protein T4 gp32 mutant and its application. The present disclosure screens T4 gp32 protein variants by using point mutation technology, and the affinity and stability of the mutant to DNA are obviously improved compared with the wild type. The T4 gp32 protein variant screened by the present disclosure can significantly improve the efficiency of the RPA reaction, greatly shorten the reaction time of the RPA reaction, and make it more suitable for basic laboratories and on-site rapid nucleic acid detection.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function through spatiochemical and spatiotemporal control over intracellular regulatory protein networks at the level of expressed gene products of nucleic acid-binding protein (NABP) genes. Subpopulation-specific cytoactive agents of the invention are used in therapeutic compositions that up- or downregulate disease-associated intracellular regulatory protein genes at the RNA and protein level for prevention and treatment of plant, animal and human diseases. Applications in human clinical medicine include biopharmaceutical preparations and associated treatment methods for genetic, degenerative, neurological, cellular and immune disorders resulting from dysregulation of endogenous NABP regulatory networks. Therapeutic compositions designed or selected for use in plants and nonhuman animals are applied to the fields of agriculture and veterinary medicine. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions across fields. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first subpopulation of a cellular protein or therapeutic target without substantially altering the activity of at least a second subpopulation of the cellular protein or therapeutic target.

The invention discloses a functionalized acupuncture needle and a surface modification method and application thereof, and the surface modification method comprises the following three steps: 1) threading the surface of a common acupuncture needle to obtain a threaded acupuncture needle; 2) modifying the surface of the threaded acupuncture needle with polydopamine to obtain a polydopamine-coated threaded acupuncture needle; and 3) modifying nucleic acid binding protein on the thread acupuncture needle wrapped by the polydopamine to obtain the functionalized acupuncture needle. The width of a threaded groove formed in the surface of the threaded acupuncture needle is 1-300 microns; and the depth of the thread groove is 10 nm to 500 nm. The surface-modified acupuncture needle has remarkable advantages. The kit is good in biocompatibility, does not bleeding when the free nucleic acid of the lymph node cells is extracted, reduces the diffusion risk, and can be used for various detections. The nucleic acid capturing efficiency is improved through threading treatment, and high-specificity adsorption is achieved through the functional coating. And the whole-flow process is adaptive to industrialization and clinical transformation, a kit can be prepared, and an efficient tool is provided for early tumor screening.